Compare LOCL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCL | SKYE |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | 286 | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 29.1M |
| IPO Year | N/A | 2013 |
| Metric | LOCL | SKYE |
|---|---|---|
| Price | $1.50 | $0.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 52.3K | ★ 169.9K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $97.19 | N/A |
| Revenue Next Year | $33.69 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.98 | $0.57 |
| 52 Week High | $4.00 | $5.75 |
| Indicator | LOCL | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 41.05 | 46.98 |
| Support Level | $1.33 | $0.71 |
| Resistance Level | $1.84 | $0.83 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 9.48 | 45.93 |
Local Bounti Corp is a controlled environment agriculture company. The business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides. The products of the company include living lettuce, leafy greens, herbs, and others.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.